SCHEMBL25413283

SCHEMBL25413283

CC(C)[C@H](NC(=O)CCCCCN1C(=O)C=CC1=O)C(=O)N[C@@H](C)C(=O)Nc1ccc(CCl)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.37
▸ PTGS1 P23219 4/20 0.37
▸ PTGS2 P35354 4/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ NR3C1 P04150 1/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ HPGD P15428 2/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ MAPT P10636 3/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ HDAC3 O15379 1/20 0.35
▸ HDAC4 P56524 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC7 Q8WUI4 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HDAC10 Q969S8 1/20 0.35
▸ HDAC11 Q96DB2 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ HDAC9 Q9UKV0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25413284 1.00 KMT2A (0.37) KMT2APTGS1PTGS2CASP1NR3C1
SCHEMBL23933301 0.92 KMT2A (0.40) KMT2APTGS1PTGS2SMN1; SMN2HPGD
SCHEMBL23933300 0.92 KMT2A (0.40) KMT2APTGS1PTGS2SMN1; SMN2HPGD
SCHEMBL31529152 0.92 NR3C1 (0.40) KMT2ACASP1NR3C1SMN1; SMN2HPGD
SCHEMBL22459925 0.91 HDAC3 (0.41) KMT2APTGS1PTGS2CASP1NR3C1
SCHEMBL21073942 0.91 KMT2A (0.38) KMT2APTGS1PTGS2CASP1NR3C1
SCHEMBL21073943 0.91 KMT2A (0.38) KMT2APTGS1PTGS2CASP1NR3C1
SCHEMBL24835046 0.91 HDAC3 (0.41) KMT2APTGS1PTGS2CASP1NR3C1
SCHEMBL20864022 0.91 KMT2A (0.38) KMT2APTGS1PTGS2CASP1NR3C1
SCHEMBL22990414 0.91 SMN1; SMN2 (0.38) KMT2APTGS1PTGS2CASP1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304563-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2025-10-02 — — US disclosed
EP-4490152-A1 ACTIVATORS OF EFFECTOR T CELLS Orum Therapeutics Inc. (KR) 2025-01-15 — — EP disclosed
WO-2023170608-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2023-09-14 — — WO disclosed
WO-2023170608-A1 ACTIVATORS OF EFFECTOR T CELLS ORUM THERAPEUTICS, INC. (KR) 2023-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304563-A1 ACTIVATORS OF EFFECTOR T CELLS CBLB, CBL, CBLC KMT2A 1486/4885PTGS1 4831/4885PTGS2 4736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback